Recent

% | $
Quotes you view appear here for quick access.

Medivation, Inc. (MDVN) Message Board

  • dumontlaw dumontlaw Apr 5, 2013 3:10 PM Flag

    Radium 223 from Bayer is the 6th similar drug

    that offers a 30% improvement from the spread of prostate cancer to the bones. This field is too crowded and too expensive.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Another new voice - probably someone who bought a few puts when the stock seemed to be showing weakness - pipes up from the wilderness with a piece of half-digested misinformation. Radium-233, which is probably a helpful drug for those in the final stages of mCRPC, will have no impact whatsoever on the prospects for Xtandi. As for the field being "crowded", you are wrong. There are no viable alternatives to Xtandi, other than Zytiga, which is a less desirable drug on a couple of counts. As for "expensive", you're right. All of these drugs are very expensive. But when you're dying and an insurance company or Medicare is picking up virtually all of the cost, this is unimportant. (At least in the US. The Europeans have a somewhat more cost-conscious approach to these issues.)

 
MDVN
125.41+4.67(+3.87%)May 1 3:59 PMEDT